Brentuximab vedotin

Brentuximab Vedotin

Structure of Brentuximab Vedotin

Brentuximab vedotin is an antibody-drug conjugate (ADC) used in the treatment of certain types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It combines the targeting ability of a monoclonal antibody with the cell-killing ability of a potent chemotherapy drug.

Mechanism of Action

Brentuximab vedotin consists of three main components:

1. Monoclonal Antibody: The antibody component is directed against CD30, a protein expressed on the surface of certain cancer cells, including those in Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

2. Linker: A protease-cleavable linker connects the antibody to the cytotoxic agent. This linker is stable in the bloodstream but releases the cytotoxic agent once inside the target cell.

3. Cytotoxic Agent: The cytotoxic component is monomethyl auristatin E (MMAE), a potent inhibitor of microtubule polymerization, which leads to cell cycle arrest and apoptosis.

Upon binding to CD30 on the surface of cancer cells, brentuximab vedotin is internalized, and the linker is cleaved, releasing MMAE into the cell. This results in the disruption of the microtubule network, leading to cell death.

Clinical Use

Brentuximab vedotin is primarily used in the treatment of:

• Hodgkin lymphoma: Particularly in patients who have relapsed or are refractory to other treatments.
• Systemic anaplastic large cell lymphoma: Especially in cases where the disease has not responded to prior therapies.

It is administered as an intravenous infusion, typically every three weeks, and the dosage is based on the patient's body weight.

Side Effects

Common side effects of brentuximab vedotin include:

• Peripheral neuropathy
• Fatigue
• Nausea
• Diarrhea
• Fever

Serious side effects can include progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection, and severe infusion reactions.

Related Pages

• Antibody-drug conjugate
• Monoclonal antibody therapy
• Chemotherapy
• Hodgkin lymphoma
• Systemic anaplastic large cell lymphoma